Nachrichten |
| Datum / Uhrzeit |
Titel |
Bewertung |
| 26.05.26 12:25:00 |
AiM Medical Robotics kündigt Zusammenarbeit mit Siemens Healthineers an, um MRI-führer Roboter-Neurochirurgie zu fördern |
 |
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
AiM Medical Robotics AiM Medical Robotics aktivierte stereotaktische Rahmen zeigt einen Siemens MAGNETOM Skyra 3T-MRI. AiMs Plattform wird eine nahtlose bidirektionale Schnittstelle für Steuerung und Bildgebung mit der gesamten Reihe von Siemens-MRI-Systemen haben. GlobeNewswire Inc. Worcester, MA, 26. Mai 2026 (GLOBE NEWSWIRE) -- AiM Medical Robotics, ein führender Entwickler von fortschrittlichen Roboter-Systemen für MRI-führer Neurochirurgie, gab heute eine Zusammenarbeit mit Siemens Healthineers für die Implementierung einer Schnittstelle bekannt, die es ermöglicht, dass AiMs Roboterplattform mit den MRI-Systemen von Siemens Healthineers betrieben werden kann. Die Schnittstelle unterstützt die Integration von AiMs kompakten, MRI-kompatiblen Roboter-Stereotaktik-Neurochirurgie-System und zugehöriger Workflow mit den Marktführern Siemens Healthineers' MAGNETOM-MRI-Scannern. Diese Schnittstellen-basierte Integration stellt einen wichtigen Schritt hin zur koordinierten Robot-MRI-Betrieb dar und bietet eine Grundlage für zukünftige Zusammenarbeitsmöglichkeiten. Aufbauend auf dieser technischen Kompatibilität sieht AiM Medical Robotics das Potenzial, um tiefergehende Ebenen der Integration zu erkunden, die darauf abzielen, Präzision und Effizienz in bildgeführten Neurochirurgie-Interventionen zu verbessern. |
| 13.05.26 08:08:50 |
Siemens Aktiengesellschaft Q2 Earnings Call Highlights |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Siemens hat im zweiten Quartal einen starken Umsatz von EUR 24,1 Milliarden erzielt. Die Orders stiegen um 18 % und die Free Cash Flow erreichte EUR 1,7 Mrd. Das Unternehmen bestätigte sein Vorjahresziel für den vergleichbaren Umsatzwachstum in der oberen Hälfte von 6 bis 8 %. |
| 12.05.26 08:30:00 |
Der Markt für klinische Informationsmanagement-Systeme wächst weltweit |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Ein Bericht von Custom Market Insights analysiert die globale Marktentwicklung und gibt Einblicke in die Zukunft des Sektors. Der Markt für klinische Informationsmanagement-Systeme (CIMS) ist ein wichtiger Teil der Gesundheitsbranche, da er die effiziente Verwaltung von Patientendaten, medizinischen Bildern und anderen relevanten Informationen ermöglicht. Laut dem Bericht wird der globale CIMS-Markt im Jahr 2025 einen Wert von über 10 Milliarden US-Dollar erreichen und bis 2030 auf etwa 15 Milliarden US-Dollar anwachsen. Der Bericht analysiert auch die treibenden Kräfte hinter diesem Wachstum, einschließlich der zunehmenden Verwendung von digitalen Gesundheitsdiensten, der steigenden Nachfrage nach effizienten Patientenverwaltungssystemen und der wachsenden Bedeutung von Datenanalyse in der Medizin. Darüber hinaus identifiziert der Bericht die wichtigsten Herausforderungen und Chancen im CIMS-Sektor, einschließlich der Notwendigkeit der Einhaltung strenger Sicherheits- und Datenschutzstandards sowie der Möglichkeit zur Entwicklung neuer Geschäftsmodelle auf Basis von Datenanalyse. Der Bericht ist eine wertvolle Ressource für alle Interessierten am CIMS-Sektor, einschließlich Unternehmen, Investoren und Forscher. |
| 08.05.26 07:01:55 |
Siemens Healthineers AG (SMMNY): Highlights der Q2-Ergebnisse 2026 - Starkes Wachstum im Bildgebungssegment |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Das Bildgebungssegment wuchs um 6,1 % und die angepasste EBIT-Marge lag bei 22,4 %. Die Precision-Therapie-Abteilung wies ein Wachstum von 4,7 % auf. Im Diagnostik-Segment gab es jedoch eine 6-prozentige Umsatzrückgang in China. Die angepassten EPS stiegen um 16 %. Der Free-Cash-Flow war stark mit einem Konversionsrate von 0,81 im Q2. |
| 06.05.26 21:17:22 |
Siemens Healthineers' CDC-Zertifizierung erneuert: Auswirkungen auf Bewertung |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Siemens Healthineers' Atellica IM Testosterone II-Assay hat seine Zertifizierung unter dem CDC-Hormonstandardisierungsprogramm erneuert. Es bleibt der einzige vollautomatisierte Immunoassay mit dieser CDC-Anerkennung, was seine Rolle bei standardisierten Testosteron-Tests hervorhebt. Die erneute Zertifizierung ist für Laboratorien und Kliniker relevant, die Konsistenz mit internationalen Hormontest-Guidelines anstreben. |
| 06.05.26 13:19:00 |
Chancenperspektiven für die 1,1 Milliarden US-Dollar starke Präklinische Bildgebung-Industrie bis 2026 - Bruker Corp., Cubresa und Siemens Healthineers führen |
 |
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Die globale Präklinische Bildgebung-Markt ist für einen robusten Wachstum geöffnet, mit einem Umsatz von 1,7 Milliarden US-Dollar bis 2033, was einer CAGR von 6,10% während der Vorhersageperiode entspricht. Die Expansion dieses Marktes wird durch die wachsende Akzeptanz präklinischer Bildgebungsverfahren in der Arzneimittelentdeckung, der translationalen Forschung und der Biomarkervalidierung getrieben, was für eine Verbesserung der Effizienz bei pharmazeutischen und biotechnologischen Forschungen unerlässlich ist. |
| 04.05.26 13:30:00 |
CDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access to Gold Standard Equivalent Results |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Siemens Healthineers
Tarrytown, NY, USA, May 04, 2026 (GLOBE NEWSWIRE) --
The Atellica TSTII Testosterone assay is the only immunoassay with CDC HoST-TT Certification Certification reaffirms assay results are aligned with specialized mass spectrometry testing method The immunoassay test is a broadly available, economical option for patients and laboratories
Siemens Healthineers announced its Atellica IM Testosterone II (TSTII) assay has achieved certification through the Centers for Disease Control and Prevention (CDC) Hormone Standardization Program for Total Testosterone (HoSt-TT). This certifies that the Atellica IM TSTII immunoassay’s test results are equivalent to high performance liquid chromatography coupled with tandem mass spectrometry, which is regarded as the gold‑standard analytical approach [1,2]. The Atellica IM TSTII assay, available on the Atellica IM and Atellica CI Analyzers, is the only fully automated immunoassay to achieve CDC HoSt-TT certification, which it has maintained continuously since 2019 [3]. An evaluation of the assay’s performance was recently published in The Journal of Clinical Endocrinology & Metabolism.
Testosterone is a key steroid hormone with essential roles in sexual development, reproductive function, musculoskeletal health, and bone metabolism. Accurate measurement of testosterone is clinically important, as abnormal levels may be associated with a wide range of endocrine, metabolic, reproductive, and oncologic conditions [2]. In clinical and research settings, total testosterone measurements are often considered alongside other biochemical and clinical factors when evaluating androgen status. High-quality, standardized testosterone assays play an important role in supporting consistent measurement and interpretation across diverse patient populations, including male, female, and pediatric patients.
“For women and children, testosterone levels are naturally low, which makes accurate measurement challenging,” said Ross Molinaro, PhD, head of Medical Value and Evidence for Diagnostics at Siemens Healthineers. “The Atellica IM TSTII Testosterone assay is currently the only fully automated immunoassay with sustained CDC HoSt-TT certification, offering a suitable and widely used routine method that is alternative to an otherwise specialty testing method, enabling clinicians to confidently support more patients.”
Certification through the HoSt-TT program ensures traceability, minimizes variability, and supports compliance with Endocrine Society and American Urological Association guidelines [4]. Ongoing certification ensures longitudinal consistency and reliable clinical interpretation of total testosterone results.
Story Continues
“The CDC’s Clinical Hormone Standardization Programs standardize the total testosterone assay so that results are accurate, comparable, and clinically meaningful wherever they are performed, said Scott D. Isaacs, MD, FACP, FACE, adjunct professor for the Department of Medicine at Emory University School of Medicine. “By calibrating assays to a common reference method and enforcing stringent performance criteria, CDC HoSt-TT reduces inter-laboratory variability. In clinical practice, this level of standardization improves the quality of care. When I review a total testosterone result, I can trust that it reflects the same analytical standard regardless of where it was performed, allowing for more consistent diagnosis and treatment decisions.”
More information about the Atellica IM TSTII assay is available here.
1 French D., (2023) Clinical utility of laboratory developed mass spectrometry assays for steroid hormone testing
2 Cook Botelho, J. et al. (2013) Isotope-Dilution Liquid Chromatography–Tandem Mass Spectrometry Candidate Reference Method for Total Testosterone in Human Serum
3 Certified Total Testosterone Assays | CDC
4 Jieli Li, et al. (2026) Evaluation of the Siemens Healthineers Atellica TSTII testosterone assay in the CDC HoSt-TT Program
Media contact
Kimberly Nissen
610-241-2129; Kimberly.nissen@siemens-healthineers.com
Visit the Siemens Healthineers Press Center. Subscribe to our “Medtech matters” newsletter on LinkedIn.
Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at siemens-healthineers.com.
Contact Info
Kimberly Nissen
kimberly.nissen@siemens-healthineers.com
+1 610-241-2129
Attachment
Press Release
View Comments |
| 22.04.26 11:34:00 |
Telehealth Market Report 2025-2036: Key Segments, Share, Regulatory, Reimbursement and Forecasts Featuring Philips Healthcare, American Well, Teladoc |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Company Logo
Telehealth offers opportunities through remote patient monitoring, key industry trends, competitive dynamics, and regulatory insights across 39 countries. It enables strategic planning, investment, and sales strategies for stakeholders, while highlighting emerging players and innovations in digital health.
Dublin, April 22, 2026 (GLOBE NEWSWIRE) -- The "Telehealth Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036" report has been added to ResearchAndMarkets.com's offering.
Telehealth Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036 is built to visualize quantitative and qualitative market trends within Digital Health therapeutic area.
The use of electronic information and telecommunications technology to support long-distance clinical health care, patient and professional health-related education, public health, and health management is known as telehealth. Technologies include videoconferencing, the internet, store-and-forward imaging, streaming media, and terrestrial and wireless communications. Telehealth has provided the much-needed solace for both patients and medical professionals. Doctors can provide patients with their medical opinion depending on the symptoms they have shown thanks to remote patient monitoring made possible via Telehealth.
Each of the covered 39 countries color-coded and fully-sourced market models are equipped with value, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insights offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Telehealth and evolving competitive landscape:
Insightful review of the key industry trends. Annualized total Telehealth market revenue by segment and market outlooks from 2015-2036. Granular data on total interventions, units, average selling prices and market values by segment.
Global, Regional and Country level market specific insights:
Qualitative market specific information is available with global trends further broken down into regional trends. In addition the analyst analysts provide unique country specific insights on the market. SWOT analysis for Telehealth. Competitive dynamics insights and trends provided for Telehealth market.
Report Scope
CMO executives who must have deep understanding of the Telehealth marketplace to make strategic planning and investment decisions. Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management. Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Story Continues
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies. Develop business strategies by understanding the trends shaping and driving Telehealth market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Telehealth market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders. Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage. Track device sales in the global and country-specific Telehealth market from 2015-2036. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Companies Featured
Philips Healthcare Informatics Inc American Well Corp Teladoc Health Inc Siemens Healthineers AG
For more information about this report visit https://www.researchandmarkets.com/r/kxrplc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
View Comments |
| 19.04.26 23:04:36 |
How The Siemens Healthineers (XTRA:SHL) Narrative Is Shifting As Analysts Revisit Price Targets |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
Siemens Healthineers has seen its modeled fair value trimmed from €55.02 to €54.02, a change of about €1 that keeps the debate squarely on price targets rather than any sweeping reset of expectations. Recent research has included both €1 to €4 cuts and a separate €2 price target increase, underscoring that analysts are splitting between slightly more cautious and slightly more optimistic views on where the shares should trade. As you read on, you will see how to track these shifting targets and what they may signal for the evolving narrative around the stock.
Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Siemens Healthineers.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
Citi has shown flexibility on Siemens Healthineers, first raising its price target by €2 in January 2026. This supports the view that there is room for upside if execution matches expectations. Even after the subsequent €1 trim in February 2026, Citi’s moves suggest the bank still sees value in the shares, with adjustments framed as fine tuning rather than a fundamental reset.
🐻 Bearish Takeaways
Deutsche Bank lowered its price target by €4 in March 2026. This signaled increased caution around how current valuation stacks up against the company’s delivery on its plans. Morgan Stanley followed in April 2026 with a further €3 reduction, which adds to the more cautious tone and highlights that some analysts see a less generous risk reward at previous target levels.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!XTRA:SHL 1-Year Stock Price Chart
We've flagged 1 risk for Siemens Healthineers. See which could impact your investment.
What's in the News
Siemens Healthineers is reviewing options for its Diagnostics business, including a possible sale. Siemens AG is looking to reduce its majority stake, and the group has indicated that revenue growth is seen as flat for fiscal years starting in 2027. The company issued earnings guidance for the second quarter of 2026, stating that revenue growth for the quarter is expected to be below its 5% to 6% outlook range. Varian TrueBeam radiotherapy systems received FDA 510(k) clearance for low dose radiation therapy in adults with medically refractory osteoarthritis, expanding use beyond cancer care into chronic musculoskeletal conditions. Dentsply Sirona and Siemens Healthineers received FDA clearance in the U.S. for the MAGNETOM Free.Max Dental Edition, described as the first dental dedicated MRI system, following a clinical trial across multiple dental specialties.
Story Continues
How This Changes the Fair Value For Siemens Healthineers
Fair value trimmed from €55.02 to €54.02, a reduction of about €1 per share. Revenue growth revised from 5.44% to 5.46% in projected € terms. Net profit margin moved from 11.24% to 11.21% of projected € revenue. Future P/E adjusted from 24.00x to 23.62x in the updated model. Discount rate adjusted from 6.55% to 6.54% in the cash flow calculations.
Never Miss an Update: Follow The Narrative
Narratives connect Siemens Healthineers' business story with the earnings forecasts and fair value models analysts are using. They refresh as new data, guidance, or newsflow is incorporated, so you can see how the thesis is evolving over time.
Head over to the Simply Wall St Community and follow the Narrative on Siemens Healthineers to stay up to date on:
How advanced imaging, AI diagnostics and digital solutions are tied to order growth, margin expectations and a larger share of recurring revenue. The role of aging populations, chronic disease trends and emerging market healthcare investment in supporting the long term demand picture. Key risks such as tariff pressures, restructuring in Diagnostics, China exposure, foreign exchange headwinds and intense competition in imaging and digital diagnostics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SHL.DE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments |
| 17.04.26 16:20:00 |
Radiology AI Global Market Research and Forecast Report 2026-2030: Opportunities in Growing Demand for Platform, Multi-Modal Data, and OEM Integration |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Company Logo
The radiology AI market is set to explode from USD 0.76 billion in 2025 to USD 2.27 billion by 2030, growing at a 24.5% CAGR. The surge is driven by the adoption of AI tools for cancer detection, lesion segmentation, and workflow optimization, particularly within oncology, neuroimaging, and cardiovascular sectors. The software/SaaS segment will dominate, offering easy deployment across platforms. North America leads in market share due to significant healthcare investments and a high prevalence of chronic conditions. Key players include Siemens Healthineers, Microsoft, and GE HealthCare. Despite challenges like data privacy, AI integration continues to gain solid ground.
Radiology AI MarketRadiology AI Market·GlobeNewswire Inc.
Dublin, April 17, 2026 (GLOBE NEWSWIRE) -- The "Radiology AI Market by Offering, Function, Modality, Indication, End User, Region - Global Forecast to 2030" has been added to ResearchAndMarkets.com's offering.
The radiology AI market is anticipated to surge from USD 0.76 billion in 2025 to USD 2.27 billion by 2030 at a CAGR of 24.5%
This report is invaluable for established and emerging firms, providing market insight strategies to enhance market presence through various approaches. It examines drivers such as increased medical imaging, AI demand to ease radiologist loads, regulatory clarity, government support, and innovation investments which drive growth in the radiology AI domain.
This growth reflects the increasing deployment of AI tools that significantly improve early cancer detection, lesion segmentation, and predictive treatment planning. Such technologies enhance diagnostic precision and alleviate radiologists' workloads, thereby boosting demand across oncology, neuroimaging, and cardiovascular imaging spheres.
The workflow optimization segment is poised for remarkable market growth.
The radiology AI market is divided into segments like screening & triage, diagnostic imaging, treatment planning, monitoring, workflow optimization, and more. Notably, workflow optimization is expected to record the fastest CAGR due to its substantial benefits in imaging department efficiency.
With a shortage of radiologists globally and increasing imaging demands, healthcare systems need AI that improves productivity via intelligent work orchestration, automated routing, and streamlined communication. These tools reduce repeat scans, aid protocol standardization, and minimize administrative workload. As value-based care gains momentum, investment in workflow AI will become a focal point for achieving cost efficiency and patient satisfaction.
Story Continues
The software/SaaS segment is projected to dominate the market by 2025.
Leading the market share, software/SaaS solutions are favored for their ease of deployment across various imaging types. They seamlessly integrate with existing systems like PACS and EHR, allowing for effortless access to AI insights. Cloud platforms enhance data access, support model improvement, and reduce initial costs. Their subscription models provide cost-effectiveness and stable recurrent revenue. Regulatory endorsements and robust use cases in crucial medical areas further cement their market strength.
North America will hold a significant market share in the radiology AI sector by 2025.
Substantial investments in healthcare technology, high imaging service demands, and swift AI incorporation into U.S. radiology practices underscore North America's market leadership. Federal support and regulatory advances have bolstered AI tool integration alongside a rising incidence of chronic diseases intensifying the need for advanced imaging solutions. Chronic conditions represent a substantial burden, representing 90% of healthcare expenditure and affecting 60% of the U.S. population.
Substantial contributions from private and public investments alongside active AI startups and tech companies bolster North America's position. Key players such as Aidoc, Enlitic, Inc., and GE HealthCare are instrumental in advancing AI-enabled diagnostic platforms.
However, challenges like data privacy regulations and clinician acceptance of AI tools continue to pose hurdles. Despite this, North America's robust healthcare infrastructure, supportive policies, and innovative AI solutions ensure its continued leadership within the radiology AI marketplace.
Key Market Players
The key firms in the radiology AI market include Siemens Healthineers AG, Microsoft, Koninklijke Philips N.V., GE HealthCare, Fujifilm Holdings Corporation, Canon Medical Systems Corporation, Merative, DeepHealth (RadNet, Inc.), Shanghai United Imaging Healthcare, Hologic, Inc., and Enlitic, Inc.
Key Attributes:
Report Attribute Details No. of Pages 347 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $0.76 Billion Forecasted Market Value (USD) by 2030 $2.27 Billion Compound Annual Growth Rate 24.5% Regions Covered Global
Key Topics Covered:
Market Dynamics
Drivers
Increasing Medical Imaging Volumes Rising Demand for AI Solutions to Alleviate Radiologist Workload Increased Regulatory Clarity, Accelerated Approvals, and Government Support Growing Demand for AI-Driven Radiological Image Processing Growing Funding for AI-Focused Startups Rising Collaborations with AI, Tech, and Analytics Solution Providers
Restraints
High Implementation Costs and ROI Uncertainty Regulatory Fragmentation Across Regions Data Quality and Label Scarcity for Rarer Indications
Opportunities
Growing Demand for Platform, Multi-Modal Data, and OEM Integration (Pacs/Ehr/Marketplaces) Untapped Growth Potential in Emerging Healthcare Markets Expansion of Preventive Care and Population Health Management Expansion of Portable/Handheld Devices with AI Integration
Challenges
Integration Challenges with Legacy Radiology Systems Limited Clinician Trust and Explainability Demands Concerns Over Data Privacy and Security
Unmet Needs & White Spaces
Interconnected Markets & Cross-Sector Opportunities
Strategic Moves by Tier-1/2/3 Players
Company Profiles
Siemens Healthineers AG Microsoft Koninklijke Philips N.V. GE Healthcare Fujifilm Holdings Corporation Canon Medical Systems Corporation (Canon Inc.) Merative Radnet, Inc. (Deephealth) Shanghai United Imaging Healthcare Co. Ltd. Hologic, Inc. Enlitic, Inc. Aidoc Viz.AI, Inc. Nanox Qure.AI Esaote S.P.A. Butterfly Network Inc. Heartflow Inc. Subtle Medical, Inc. Harisson.AI Echonous Inc. Quibim Imagen Exo Imaging, Inc. Rad AI
For more information about this report visit https://www.researchandmarkets.com/r/kht9p8
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Radiology AI Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
View Comments |
